-+ 0.00%
-+ 0.00%
-+ 0.00%

STOKE THERAPEUTICS AND BIOGEN PRESENT LONG-TERM CLINICAL DATA THAT SUPPORT THE DISEASE-MODIFYING POTENTIAL OF ZOREVUNERSEN, AN INVESTIGATIONAL MEDICINE FOR THE TREATMENT OF DRAVET SYNDROME, AT THE 16TH EUROPEAN EPILEPSY CONGRESS (EEC)

Reuters·09/03/2026 23:30:00

Please log in to view news